PTC Therapeutics, Inc. (PTCT)
NASDAQ$54.5+1.74 (3.30%)
Market Cap
$4.16B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
792 of 924
Rank in Industry
444 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
PTCT Insider Trading Activity
PTCT Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $22,642,041 | 46 | 100 |
Related Transactions
| Jacobson Allan Steven | director | 0 | $0 | 1 | $63,370 | $-63,370 |
| Gravier Pierre | CHIEF FINANCIAL OFFICER | 0 | $0 | 3 | $194,207 | $-194,207 |
| Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | 0 | $0 | 6 | $198,748 | $-198,748 |
| Pauwels Eric | CHIEF EXECUTIVE OFFICER | 0 | $0 | 5 | $334,909 | $-334,909 |
| Klein Matthew B. | CHIEF EXECUTIVE OFFICER | 0 | $0 | 7 | $1.08M | $-1.08M |
| Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | 0 | $0 | 5 | $1.14M | $-1.14M |
| ZELDIS JEROME B | director | 0 | $0 | 2 | $2M | $-2M |
| Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 0 | $0 | 5 | $4.01M | $-4.01M |
| Boulding Mark Elliott | EXEC. VP AND CLO | 0 | $0 | 12 | $13.61M | $-13.61M |
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic …
Insider Activity of PTC Therapeutics, Inc.
Over the last 12 months, insiders at PTC Therapeutics, Inc. have bought $0 and sold $22.64M worth of PTC Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at PTC Therapeutics, Inc. have bought $424,214 and sold $25.12M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 7,700 shares for transaction amount of $198,736 was made by Gravier Pierre (CHIEF FINANCIAL OFFICER) on 2023‑12‑12.
List of Insider Buy and Sell Transactions, PTC Therapeutics, Inc.
| 2025-03-11 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 7,381 0.0094% | $53.02 | $391,323 | +1.13% | |
| 2025-03-11 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 1,719 0.0022% | $53.01 | $91,124 | +1.13% | |
| 2025-03-10 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 68,039 0.0872% | $53.09 | $3.61M | +0.51% | |
| 2025-03-10 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 60,277 0.0773% | $53.09 | $3.2M | +0.51% | |
| 2025-03-04 | Sale | Jacobson Allan Steven | director | 1,230 0.0015% | $51.52 | $63,370 | +1.53% | |
| 2025-02-20 | Sale | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | 3,895 0.005% | $50.12 | $195,233 | +4.52% | |
| 2025-02-20 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 1,614 0.0021% | $50.12 | $80,900 | +4.52% | |
| 2025-02-20 | Sale | Pauwels Eric | CHIEF EXECUTIVE OFFICER | 1,567 0.002% | $50.12 | $78,544 | +4.52% | |
| 2025-02-20 | Sale | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | 962 0.0012% | $50.12 | $48,219 | +4.52% | |
| 2025-02-20 | Sale | Gravier Pierre | CHIEF FINANCIAL OFFICER | 1,167 0.0015% | $50.12 | $58,495 | +4.52% | |
| 2025-02-20 | Sale | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | 878 0.0011% | $50.12 | $44,009 | +4.52% | |
| 2025-02-20 | Sale | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 1,612 0.0021% | $50.12 | $80,800 | +4.52% | |
| 2025-02-19 | Sale | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | 3,897 0.0051% | $50.10 | $195,224 | +3.39% | |
| 2025-02-19 | Sale | Boulding Mark Elliott | EXEC. VP AND CLO | 1,333 0.0018% | $50.10 | $66,778 | +3.39% | |
| 2025-02-19 | Sale | Pauwels Eric | CHIEF EXECUTIVE OFFICER | 1,378 0.0018% | $50.10 | $69,032 | +3.39% | |
| 2025-02-19 | Sale | Golden Lee Scott | EVP & CHIEF MEDICAL OFFICER | 795 0.001% | $50.10 | $39,826 | +3.39% | |
| 2025-02-19 | Sale | Gravier Pierre | CHIEF FINANCIAL OFFICER | 1,168 0.0015% | $50.10 | $58,512 | +3.39% | |
| 2025-02-19 | Sale | Utter Christine Marie | SVP, CHIEF ACCOUNTING OFFICER | 879 0.0012% | $50.10 | $44,034 | +3.39% | |
| 2025-02-19 | Sale | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | 1,334 0.0018% | $50.10 | $66,828 | +3.39% | |
| 2025-01-08 | Sale | Klein Matthew B. | CHIEF EXECUTIVE OFFICER | 2,402 0.0031% | $44.50 | $106,889 | +10.61% |
Total: 322
*Gray background shows transactions not older than one year
Insider Historical Profitability
21.11%
| Gravier Pierre | CHIEF FINANCIAL OFFICER | 74436 0.0944% | $3.93M | 1 | 3 | +25.22% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2441504 3.0956% | $128.81M | 1 | 1 | +8.52% |
| Koppel Adam | director | 2333333 2.9585% | $123.11M | 1 | 0 | +8.52% |
| Vulcan Ventures Inc. | director | 803067 1.0182% | $42.37M | 1 | 0 | +8.52% |
| SCHMERTZLER MICHAEL | director | 115266 0.1461% | $6.08M | 5 | 2 | +30.17% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$159,914,414 | 243 | 18.52% | $5.79B | |
$52,263,649 | 70 | 1.18% | $4.23B | |
$11,859,102 | 17 | 18.62% | $5.26B | |
$128,181,928 | 16 | 18.84% | $3.29B | |
$74,605,681 | 14 | 47.06% | $3.6B |
PTCT Institutional Investors: Active Positions
| Increased Positions | 138 | +61.33% | 11M | +13.76% |
| Decreased Positions | 98 | -43.56% | 9M | -10.89% |
| New Positions | 58 | New | 5M | New |
| Sold Out Positions | 22 | Sold Out | 1M | Sold Out |
| Total Postitions | 265 | +17.78% | 81M | +2.87% |
PTCT Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $507,222.00 | 11.62% | 9.18M | +53,688 | +0.59% | 2024-12-31 |
| Blackrock, Inc. | $436,488.00 | 10% | 7.9M | -84,412 | -1.06% | 2024-12-31 |
| Rtw Investments, Lp | $408,544.00 | 9.36% | 7.39M | 0 | 0% | 2024-12-31 |
| Armistice Capital, Llc | $352,448.00 | 8.07% | 6.38M | -856,898 | -11.84% | 2024-12-31 |
| Wellington Management Group Llp | $264,536.00 | 6.06% | 4.79M | -3M | -39.35% | 2024-12-31 |
| Cowen And Company, Llc | $198,420.00 | 4.55% | 3.59M | -165,814 | -4.41% | 2024-09-30 |
| Toronto Dominion Bank | $181,625.00 | 4.16% | 3.29M | +3M | New | 2024-12-31 |
| Camber Capital Management Lp | $176,832.00 | 4.05% | 3.2M | -300,000 | -8.57% | 2024-12-31 |
| State Street Corp | $149,644.00 | 3.43% | 2.71M | -191,044 | -6.59% | 2024-12-31 |
| Janus Henderson Group Plc | $128,530.00 | 2.94% | 2.33M | +455,698 | +24.37% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.